Search results for "FACTOR PATHWAY INHIBITOR"

showing 9 items of 9 documents

Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis

2019

Antiphospholipid antibodies (aPLs) with complex lipid and/or protein reactivities cause complement-dependent thrombosis and pregnancy complications. Although cross-reactivities with coagulation regulatory proteins contribute to the risk for developing thrombosis in patients with antiphospholipid syndrome, the majority of pathogenic aPLs retain reactivity with membrane lipid components and rapidly induce reactive oxygen species-dependent proinflammatory signaling and tissue factor (TF) procoagulant activation. Here, we show that lipid-reactive aPLs activate a common species-conserved TF signaling pathway. aPLs dissociate an inhibited TF coagulation initiation complex on the cell surface of m…

Male0301 basic medicineLipoproteinsImmunologyPlenary Paper030204 cardiovascular system & hematologyBiochemistryMonocytesThromboplastinProinflammatory cytokine03 medical and health sciencesTissue factor0302 clinical medicineTissue factor pathway inhibitorThrombinimmune system diseasesmedicineAnimalsHumansThromboplastinBlood CoagulationneoplasmsCells CulturedNADPH oxidasebiologyChemistryThrombosisCell BiologyHematologyComplement systemMice Inbred C57BL030104 developmental biologyAntibodies Antiphospholipidbiology.proteinCancer researchFemaleSignal transductionSignal Transductionmedicine.drugBlood
researchProduct

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the A…

2007

Summary. Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. Patients/methods: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UF…

Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsLipoproteinsMyocardial InfarctionRisk AssessmentSeverity of Illness IndexAngina PectorisThromboplastinCoronary artery diseaseCohort StudiesTissue factor pathway inhibitorPredictive Value of TestsInternal medicineGermanymedicineHumansMyocardial infarctionProspective StudiesAgedProportional Hazards ModelsUnstable anginabusiness.industryHazard ratioCoronary StenosisHematologySyndromeMiddle Agedmedicine.diseasePrognosisThrombosisCardiovascular DiseasesCardiologyFemalebusinessBiomarkersBlood drawingFollow-Up StudiesJournal of thrombosis and haemostasis : JTH
researchProduct

Gpibα Engagement Induces Activation of Human Platelet TF and Association with Constitutively Platelet Surface-Bound FVIIa

2019

The membranes of activated platelets assemble clotting protein complexes and enzymatic reactions needed for hemostasis and causing pathological thrombosis. Several reports have shown that human platelets contain TF, but controversies remain on the functional contributions of platelet TF to coagulation initiation. Here, we delineate the mechanism that converts platelet-associated TF to a procoagulant molecule. By combining specific inhibitors with human platelets from normal probands or patients with Glanzmann thrombasthenia or homozygous GPVI deficiency, we analyzed the procoagulant activation of platelet TF by biochemical methods, confocal microscopy, platelet adhesion under flow on VWF an…

Glanzmann's thrombastheniaChemistryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryCell biologychemistry.chemical_compoundTissue factor pathway inhibitorThrombinCoagulationmedicinePlateletPlatelet activationGPVIRistocetinmedicine.drugBlood
researchProduct

Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor.

2018

: Tissue factor (TF) pathway inhibitor (TFPI) is an endogenous natural anticoagulant that readily inhibits the extrinsic coagulation initiation complex (TF-FVIIa-Xa) and prothrombinase (FXa, FVa and calcium ions). Alternatively, spliced TFPI isoforms (α, β and δ) are expressed by vascular and extravascular cells and regulate thrombosis and haemostasis, as well as cell signalling functions of TF complexes via protease-activated receptors (PARs). Proteolysis of TFPI plays an important role in regulating physiological roles of the TF pathway in host defense and possibly haemostasis. Elimination of TFPI inhibition has therefore been proposed as an approach to improve haemostasis in haemophilia …

0301 basic medicineProteasesCell signalingProteolysisLipoproteinsEndogeny030204 cardiovascular system & hematology03 medical and health sciencesTissue factor0302 clinical medicineTissue factor pathway inhibitorProthrombinasemedicineAnimalsHumansRNA Processing Post-TranscriptionalReceptorHemostasismedicine.diagnostic_testChemistryThrombosisHematologyGeneral MedicineCell biology030104 developmental biologyProtein Processing Post-TranslationalBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Thrombin generation in cardiovascular disease and mortality – results from the Gutenberg Health Study

2020

Thrombin generation may be a potential tool to improve risk stratification for cardiovascular diseases. The aim of this study was to explore the relation between thrombin generation and cardiovascular risk factors, cardiovascular diseases, and total mortality. For this study, 5,000 subjects from the population-based Gutenberg Health Study were analyzed in a highly standardized setting. Thrombin generation was assessed by the Calibrated Automated Thrombogram method at 1 and 5 pM tissue factor triggers in platelet-poor plasma. Lag time, endogenous thrombin potential, and peak height were derived from the thrombin generation curve. Sex-specific multivariable linear regression analysis adjusted…

medicine.medical_specialtyPercentilePopulationDiseaseDETERMINANTS030204 cardiovascular system & hematologyFACTOR PATHWAY INHIBITORVALIDATIONArticle03 medical and health sciencesTissue factor0302 clinical medicineInternal medicineMedicineeducationPlatelet-poor plasmaeducation.field_of_studyCOAGULATION-FACTORSPLASMAbusiness.industryProportional hazards modelCALIBRATED AUTOMATED THROMBOGRAMHazard ratioORAL-CONTRACEPTIVESHematologymedicine.diseaseObesityTISSUE FACTOROBESITYATRIAL-FIBRILLATIONCardiologybusiness030215 immunologyHaematologica
researchProduct

Biological properties of extracellular vesicles and their physiological functions

2015

The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202). In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive invest…

ProteomicsCellular distributionMATURE DENDRITIC CELLSReviewReview ArticleUrineEmbryo developmentMonocyteProtein processingVascular biologyFecesVesícules seminalsSYNCYTIOTROPHOBLAST MICROVILLOUS MEMBRANESCell selectionPregnancyT lymphocyteBileCELL-DERIVED EXOSOMESBiogenesisLung lavageUterus fluidInnate immunityMale genital systemlcsh:CytologyMicrovesicleOUTER-MEMBRANE VESICLESBlood clottingprokaryoteEukaryotaExtracellular vesicleRNA analysisCell biologyBloodCerebrospinal fluidLiver metabolismmicrovesicleMorphogenHumanNervous systemCell signalingBreast milkNatural killer cellFisiologiaExtracellular vesiclesExosomelcsh:QH573-671SalivaBiologyBiology and Life SciencesDNAPlantRNA transportCell functionMacrophageMolecular biologyPhysiologyMedizinProteomicsFACTOR PATHWAY INHIBITOReukaryoteProtein glycosylationExtracellular spaceTissue repairEspai extracel·lularReticulocyteSeminal plasmaMesenchymal stem cellAntigen presenting cellSeminal vesiclesNose mucusBiofilmNeutrophilMicroRNAPLANT-MICROBE INTERACTIONSLipidAmnion fluidProkaryotamicroparticleCell interactionCell transporteukaryote exosome extracellular vesicle microparticle microvesicle physiology prokaryoteBone mineralizationMicroorganismHistologyAdaptive immunityMembrane vesicleComputational biologyMembrane receptorBiologyStressCell communicationMast cellMESENCHYMAL STEM-CELLSHUMAN ENDOTHELIAL-CELLSexosomeCytokineSynovial fluidCell BiologyNonhumanIMMUNE-MODULATORY FEATURESReview articleDNA contentphysiologyRNAINTESTINAL EPITHELIAL-CELLSextracellular vesicleBody fluidLectinBiogenesis
researchProduct

Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample

2018

Abstract Background: Tissue factor pathway inhibitor (TFPI), a Kunitz-type serine protease, is a potent anticoagulant protein in the extrinsic coagulation pathway and acts by inhibiting both the FXa and the Tissue Factor-FVIIa complex. In contrast to total and free TFPI antigen levels, the reference values and clinical determinants of total TFPI activity have not yet been studied in detail in the general population. In the present study, we aim to identify the cardiovascular determinants for total TFPI activity and investigate its association with cardiovascular disease (CVD) and total mortality, in a population at large. Methods: For this study, the first 4779 subjects of the population-ba…

business.industryImmunologyCardiovascular risk factorsCoronary arteriosclerosisLarge populationCell BiologyHematologyPharmacologymedicine.diseaseBiochemistryObesityTissue factor pathway inhibitorReference valuesDiabetes mellitusMedicinePlateletbusinessBlood
researchProduct

Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample.

2021

Abstract Objective Tissue factor pathway inhibitor (TFPI) is a potent anticoagulant protein in the extrinsic coagulation pathway. In the present study, we aim to identify the cardiovascular determinants for total TFPI activity and its association with cardiovascular disease (CVD) and total mortality. Methods Total TFPI activity was assessed in a selection of the population-based Gutenberg Health Study (n = 5,000). Statistical analysis was performed to identify the determinants for total TFPI activity as well as the associations with CVD and mortality. Results Multivariable linear regression analysis identified smoking (β 0.095 [0.054–0.136]) as a positive determinant for total TFPI activity…

cardiovascular risk factorsAdultMalemedicine.medical_specialtyLipoproteinsPopulationpopulationCoronary Artery DiseaseTFPICoronary artery diseaseTissue factor pathway inhibitorDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansObesityProspective StudieseducationAgededucation.field_of_studyVENOUS THROMBOEMBOLISMbiologyPLASMAProportional hazards modelbusiness.industrySmokingFactor VWOMENHematologyMiddle Agedmedicine.diseaseObesitymortalitytotal TFPI activityESTROGENEndocrinologyMYOCARDIAL-INFARCTIONFACTOR-VCardiovascular DiseasesHeart Disease Risk Factorsbiology.proteinPopulation studyepidemiologyFemalebusinessThrombosis and haemostasis
researchProduct

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models

2021

BACKGROUND: CD248 is a pro-inflammatory, transmembrane glycoprotein expressed by vascular smooth muscle cells (VSMC), monocytes/macrophages, and other cells of mesenchymal origin. Its distribution and properties are reminiscent of those of the initiator of coagulation, tissue factor (TF). OBJECTIVE: We examined whether CD248 also participates in thrombosis. METHODS: We evaluated the role of CD248 in coagulation using mouse models of vascular injury, and by assessing its functional interaction with the TF-factor VIIa (FVIIa)-factor X (FX) complex. RESULTS: The time to ferric chloride-induced occlusion of the carotid artery in CD248 knockout (KO) mice was significantly longer than in wild-typ…

InflammationFactor VIIa030204 cardiovascular system & hematologyInferior vena cavaArticleThromboplastin03 medical and health sciencesTissue factorchemistry.chemical_compoundMice0302 clinical medicineThrombinTissue factor pathway inhibitorAntigens CDAntigens NeoplasmmedicineAnimalsHumansMice KnockoutVenous Thrombosismedicine.diagnostic_testFactor XHematologyCoagulationchemistrymedicine.veinCancer researchProthrombin Timemedicine.symptommedicine.drugPartial thromboplastin time
researchProduct